Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review

We conducted a literature review to assess the mechanisms, efficacy and therapeutic value of psilocybin, with a focus on the peer-reviewed preclinical literature. As a result, we identified 35 papers based on our search criteria. Psilocybin seems to display the most efficacy for depressive-like and anxiety-like behaviours, but also shows considerable therapeutic value for compulsive-spectrum and fear-related disorders. Psilocybin seems to exert its therapeutic effects by altering functional connectivity patterns and modulating neuroplasticity (including associated molecular and cellular mediators). The role of the 5-HT2A receptor, and associated serotonergic signaling,  in the therapeutic effects of psilocybin requires further elucidation, as do downstream molecular, cellular and systems mechanisms. AbstractPsilocybin is the main psychoactive compound found in hallucinogenic/magic mushrooms and can bind to both serotonergic and tropomyosin receptor kinase b (TrkB) receptors. Psilocybin has begun to show efficacy for a range of neuropsychiatric conditions, including treatment-resistant depression and anxiety disorders; however, neurobiological mechanisms are still being elucidated. Clinical research has found that psilocybin can alter functional connectivity patterns in human brains, which is often associated with therapeutic outcomes. However, preclinical research affords the opportunity to assess the potential cellular mechanisms by which psilocybin may exert its therapeuti...
Source: Journal of Neurochemistry - Category: Neuroscience Authors: Tags: REVIEW Source Type: research